2024 Conference Publication DNA methylation discriminates between responder and non-responder status in a long-term study of cladribine tablet use in multiple sclerosisMaltby, Vicki E., Xavier, Alexandre, Monif, Mastura, Min, Myintzu, Fabis-Pedrini, Marzena J., Buzzard, Katherine, Kalincik, Tomas, Kermode, Allan G., Taylor, Bruce, Hodgkinson, Suzanne, McCombe, Pamela, Osborne, Meaghan, Butzkueven, Helmut, Barnett, Michael, Lea, Rodney A. and Lechner-Scott, Jeannette (2024). DNA methylation discriminates between responder and non-responder status in a long-term study of cladribine tablet use in multiple sclerosis. Multiple Sclerosis Australia: Progress in MS Research Conference (MS), Perth, WA, Australia, 29 November - 1 December 2023. London, United Kingdom: Sage Publications. |
2024 Conference Publication The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSharmin, Sifat, Roos, Izanne, Simpson-Yap, Steve, Malpas, Charles, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Kermode, Allan, Butler, Ernest, Barnett, Michael, Hodgkinson, Suzanne, McCombe, Pamela, Taylor, Bruce, Slee, Mark, Macdonell, Richard, Garber, Justin, Shaw, Cameron, Shuey, Neil, Massey, Jennifer, Hardy, Todd, Parratt, John and Kalincik, Tomas (2024). The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Multiple Sclerosis Australia: Progress in MS Research Conference (MS), Perth, WA, Australia, 29 November - 1 December 2023. London, United Kingdom: Sage Publications. |
2024 Conference Publication Closing the gap in diagnosis of neuropathies and late-onset neurological disorders - a trans-Australia collaborationLaing, N., Kennerson, M., Lamont, P., Vucic, S., Davis, M., Bryson-Richardson, R., Ravenscroft, G., Perez-Siles, G., Ghaoui, R., Narayanan, R., McCombe, P., Deveson, I., Bryen, S., Grosz, B., Johari, M., Rick, A., Folland, C., Scriba, C., Parmar, J. and Ellis, M. (2024). Closing the gap in diagnosis of neuropathies and late-onset neurological disorders - a trans-Australia collaboration. 29th International Congress of the World-Muscle-Society (WMS), Prague, Czech Republic, 8-12 October 2024. London, United Kingdom: Elsevier. doi: 10.1016/j.nmd.2024.07.328 |
2024 Conference Publication Real-world Australian experience with Ofatumumab in the MSBase RegistryBarnett, Michael, van der Walt, Anneke, Butzkueven, Helmut, Kalincik, Tomas, Spelman, Tim, Kermode, Allan, Fabis-Pedrini, Marzena, Carroll, William M., Lechner-Scott, Jeannette, John, Nevin, Hodgkinson, Suzanne, McCombe, Pamela, Macdonell, Richard, Slee, Mark, Migocki, Margaret, Martel, Kate and Schmitt, Birte (2024). Real-world Australian experience with Ofatumumab in the MSBase Registry. 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 18-20 September 2024. London, United Kingdom: Sage Publications. |
2024 Conference Publication Real-world experience with Cladribine (Mavenclad) in the MSBase registryButzkueven, Helmut, Spelman, Tim, Van der Walt, Anneke, Hodgkinson, Suzanne, Ozakbas, Serkan, Alroughani, Raed, Kalincik, Tomas, Eichau, Sara, Boz, Cavit, Buzzard, Katherine, Habek, Mario, John, Nevin, Kermode, Allan G., Foschi, Matteo, McCombe, Pamela, Gerlach, Oliver, Prevost, Julie, Meca-Lallana, Jose E., Lapointe, Emmanuelle and Jarvinen, Elina (2024). Real-world experience with Cladribine (Mavenclad) in the MSBase registry. 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 18-20 September 2024. London, United Kingdom: Sage Publications. |
2024 Conference Publication Employing Novel Indirect Treatment Comparison Methodologies to Differentiate the Efficacy of Ofatumumab and Other High Efficacy Therapies versus Orally Administered Disease Modifying Therapies for Relapsing Multiple SclerosisNelson, Morag, Butzkueven, Helmut, Van der Walt, Anneke, Broadley, Simon, Riley, Nicholas, Adlard, Nicholas, Merschhemke, Martin, Stoneman, Dee, McCombe, Pamela, Barnett, Michael, Walker, Rob, Samjoo, Imtiaz, Haltner, Anja and Drudge, Chris (2024). Employing Novel Indirect Treatment Comparison Methodologies to Differentiate the Efficacy of Ofatumumab and Other High Efficacy Therapies versus Orally Administered Disease Modifying Therapies for Relapsing Multiple Sclerosis. 16th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis, Bangkok, Thailand, 30 October - 2 November 2024. London, United Kingdom: Sage Publications. |
2024 Conference Publication Real-world Australian experience with Ofatumumab in the MSBase registryMigocki, Margaret, Walt, Anneke Van der, Butzkueven, Helmut, Spelman, Tim, Kermode, Allan, Fabis-Pedrini, Marzena, Carroll, William M., Lechner-Scott, Jeannette, John, Nevin, Barnett, Michael, Hodgkinson, Suzanne, McCombe, Pamela, Kalincik, Tomas, Macdonell, Richard, Slee, Mark and Schmitt, Birte (2024). Real-world Australian experience with Ofatumumab in the MSBase registry. ANZAN Annual Scientific Meeting 2024, Adelaide, SA Australia, 21-24 May 2024. London, United Kingdom: BMJ Group. doi: 10.1136/bmjno-2024-anzan.127 |
2024 Conference Publication Utilisation of high efficacy therapy for managing multiple sclerosis in AustraliaMcCombe, Pamela, Butzkueven, Helmut, Samjoo, Imtiaz, Barnett, Michael, Broadley, Simon, Walt, Anneke Van der, Merschhemke, Martin, Adlard, Nicholas, Burke, Naomi, Riley, Nicholas and Walker, Rob (2024). Utilisation of high efficacy therapy for managing multiple sclerosis in Australia. ANZAN Annual Scientific Meeting 2024, Adelaide, SA Australia, 21-24 May 2024. London, United Kingdom: BMJ Group. doi: 10.1136/bmjno-2024-anzan.23 |
2023 Conference Publication Novel real world evidence from MSGo, a digital support program for secondary progressive multiple sclerosis patients in Australia using SiponimodHardy, Todd, Aouad, Patrick, Barnett, Michael, Blum, Stefan, Broadley, Simon, Carroll, William, Crimmins, Denis, Griffiths, Dayna, Hodgkinson, Suzanne, Lechner-Scott, Jeannette, Lee, Andrew, Malhotra, Ram, McCombe, Pamela, Parratt, John, Plummer, Christopher, Van der Walt, Anneke, Martel, Kate and Walker, Rob (2023). Novel real world evidence from MSGo, a digital support program for secondary progressive multiple sclerosis patients in Australia using Siponimod. PACTRIMS 2022: 12th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis, Singapore, Singapore, 24-26 November 2022. London, United Kingdom: Sage Publications. |
2022 Conference Publication Comparison of the effectiveness of ocrelizumab vs interferon β, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosisRoos, Izanne, Sharmin, Sifat, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, Walt, Anneke van der, Butzkueven, Helmut, Butler, Ernest, MacDonell, Richard, McCombe, Pamela, Slee, Mark, Malpas, Charles and Kalincik, Tomas (2022). Comparison of the effectiveness of ocrelizumab vs interferon β, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis. ANZAN Annual Scientific Meeting 2022, Melbourne, VIC Australia, 10-13 May 2022. London, United Kingdom: BMJ. doi: 10.1136/bmjno-2022-anzan.26 |
2022 Conference Publication Latitude, UVR and multiple sclerosis severityVitkova, Marianna, Diouf, Ibrahima, Malpas, Charles, Barnett, Michael, Hodgkinson, Suzanne, Butler, Ernest, Slee, Mark, Taylor, Bruce, Butzkueven, Helmut, Lechner-Scott, Jeanette, McCombe, Pamela, Vucic, Steve, Macdonell, Richard, Shaw, Cameron and Kalincik, Tomas (2022). Latitude, UVR and multiple sclerosis severity. ANZAN Annual Scientific Meeting 2022, Melbourne, VIC Australia, 10-13 May 2022. London, United Kingdom: BMJ. doi: 10.1136/bmjno-2022-anzan.29 |
2021 Conference Publication Real-world experience with cladribine tablets in the MSBase Registry (2942)Butzkueven, Helmut, Spelman, Timothy, Hodgkinson, Suzanne, Kalincik, Tomas, Buzzard, Katherine, Skabina, Olga, Madueño, Sara Eichau, Ayuso, Guillermo Izquierdo, Van der Walt, Anneke, Grand-Maison, Francois, Butler, Ernest, Prevost, Julie, McCombe, Pamela, Oh, Jiwon, Macdonell, Richard, Lechner-Scott, Jeannette, Van Pesch, Vincent, Duquette, Pierre, Prat, Alexandre, Girard, Marc, Kermode, Allan and Fabris, Jessica (2021). Real-world experience with cladribine tablets in the MSBase Registry (2942). 2021 AAN 73rd Annual Meeting, Virtual, 17-22 April 2021. Philadelphia, PA USA: Wolters Kluwer Health. doi: 10.1212/wnl.96.15_supplement.2942 |
2021 Conference Publication MRI patterns distinguish neuromyelitis optica spectrum disorder from multiple sclerosisClarke, Laura, Arnett, Simon, Bukhari, Wajih, Khalilidehkordi, Elham, Sanchez, Sofia Jimenez, O’Gorman, Cullen, Prain, Kerri, Woodhall, Mark, Silvestrini, Roger, Bundell, Christine, Abernethy, David, Bhuta, Sandeep, Blum, Stefan, Boggild, Mike, Boundy, Karyn, Brew, Bruce, Brownlee, Wallace, Butzkueven, Helmut, Carroll, William, Chen, Celia, Coulthard, Alan, Dale, Russell, Das, Chandi, Fabis-Pedrini, Marzena, Fulcher, David, Gillis, David, Hawke, Simon, Heard, Robert, Henderson, Andrew ... Broadley, Simon (2021). MRI patterns distinguish neuromyelitis optica spectrum disorder from multiple sclerosis. AAN 73rd Annual Meeting, Online, 17-22 April 2021. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.96.15_supplement.4128 |
2021 Conference Publication Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)Diouf, Ibrahima, Malpas, Charles, Horakova, Dana, Havrdova, Eva, Patti, Francesco, Shaygannejad, Vahid, Ozakbas, Serkan, Ayuso, Guillermo Izquierdo, Madueño, Sara Eichau, Zakaria, Magd, Onofrj, Marco, Lugaresi, Alessandra, Alroughani, Raed, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Terzi, Murat, Boz, Cavit, Grand’Maison, Francois, Hamdy, Sherif, Sola, Patrizia, Ferraro, Diana, Grammond, Pierre, Turkoglu, Recai, Butzkueven, Helmut, Yamout, Bassem, Altintas, Ayse, Van Pesch, Vincent, Maimone, Davide ... Kalincik, Tomas (2021). Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107). AAN 73rd Annual Meeting, Online, 17-22 April 2021. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.96.15_supplement.4107 |
2020 Conference Publication Determinants of Therapeutic Lag in Multiple SclerosisRoos, Izanne, Leray, Emmanuelle, Frascoli, Federico, Casey, Romain, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Ayuso, Guillermo Izquierdo, Madueno, Sara Eichau, Patti, Francesco, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, Ozakbas, Serkan, Sola, Patrizia, Ferraro, Diana, Bergamaschi, Roberto, Cartechini, Elisabetta, Sa, Maria Jose, Boz, Cavit, Grand-Maison, Francois, Lechner-Scott, Jeannette, Terzi, Murat, Granella, Franco, Alroughani, Raed, Iuliano, Gerardo ... Kalincik, Tomas (2020). Determinants of Therapeutic Lag in Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
2020 Conference Publication Real world safety of Alemtuzumab in the treatment of Multiple Sclerosis – Australian cohort studyCorbett, Joel, Blum, Stefan, Boggild, Mike, Broadley, Simon and McCombe, Pamela (2020). Real world safety of Alemtuzumab in the treatment of Multiple Sclerosis – Australian cohort study. 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.1499 |
2020 Conference Publication Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple SclerosisKalincik, Tomas, Diouf, Ibrahima, Malpas, Charles, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Ayuso, Guillermo Izquierdo, Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Shaygannejad, Vahid, Alroughani, Raed, Hupperts, R. M. M., Terzi, Murat, Boz, Cavit, Lechner-Scott, Jeannette, Cartechini, Elisabetta, Van Pesch, Vincent, Iuliano, Gerardo, Granella, Franco, Bergamaschi, Roberto, Fernandez Bolanos, Ricardo ... Butzkueven, Helmut (2020). Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
2020 Conference Publication Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 YearsCelius, Elisabeth G., Oh, Jiwon, Achiron, Anat, Compston, D Alastair S., Devonshire, Virginia, Hellwig, Kerstin, Hutton, George J., McCombe, Pamela, Moore, Marie, Simm, Renata Faria, Sousa, Livia, Vincent, Stephen G., Chung, Luke, Daizadeh, Nadia, Mitchell, Colin and Rog, David (2020). Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 Years. 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.169 |
2020 Conference Publication Predicting Long-Term Sustained Disability Progression in Multiple SclerosisSharmin, Sifat, Bovis, Francesca, Malpas, Charles, Horakova, Dana, Havrdova, Eva, Ayuso, Guillermo Izquierdo, Eichau, Sara, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Hupperts, R. M. M., Alroughani, Raed, Boz, Cavit, Shaygannejad, Vijay, Van Pesch, Vincent, Kappos, Ludwig, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Turkoglu, Recai, Solaro, Claudio, Ramo-Tello, Cristina ... Kalincik, Tomas (2020). Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
2020 Conference Publication Cladribine: a multicentre LOng-term efficacy Biomarker Australian Study (CLOBAS)Maltby, Vicki, Lydon, Amanda, Monif, Mastura, Kilpatrick, Trevor, Butzkueven, Helmut, Taylor, Bruce, McCombe, Pamela, Hodgkinson, Suzanne, Fabis-Pedrini, Marzena, Kermode, Allan, Barnett, Michael, Kalincik, Tomas and Lechner-Scott, Jeannette (2020). Cladribine: a multicentre LOng-term efficacy Biomarker Australian Study (CLOBAS). 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.5285 |